<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id>
<journal-id journal-id-type="publisher-id">ijms</journal-id>
<journal-title-group>
<journal-title>International Journal of Molecular Sciences</journal-title>
</journal-title-group>
<issn pub-type="epub">1422-0067</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32074998</article-id>
<article-id pub-id-type="pmc">7072873</article-id>
<article-id pub-id-type="doi">10.3390/ijms21041286</article-id>
<article-id pub-id-type="publisher-id">ijms-21-01286</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>PPP2R5D-Related Intellectual Disability and Neurodevelopmental Delay: A Review of the Current Understanding of the Genetics and Biochemical Basis of the Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Biswas</surname>
<given-names>Dayita</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-21-01286">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cary</surname>
<given-names>Whitney</given-names>
</name>
<xref ref-type="aff" rid="af2-ijms-21-01286">2</xref>
<xref ref-type="aff" rid="af3-ijms-21-01286">3</xref>
<xref ref-type="corresp" rid="c1-ijms-21-01286">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nolta</surname>
<given-names>Jan A.</given-names>
</name>
<xref ref-type="aff" rid="af1-ijms-21-01286">1</xref>
<xref ref-type="aff" rid="af2-ijms-21-01286">2</xref>
<xref ref-type="aff" rid="af3-ijms-21-01286">3</xref>
<xref ref-type="corresp" rid="c1-ijms-21-01286">*</xref>
</contrib>
</contrib-group>
<aff id="af1-ijms-21-01286"><label>1</label>SPARK Program Scholar, Institute for Regenerative Cures, University of California, Sacramento, CA 95817, USA; <email>biswasd3779@student.sanjuan.edu</email></aff>
<aff id="af2-ijms-21-01286"><label>2</label>Stem Cell Program, UC Davis School of Medicine. The University of California, Sacramento, CA 95817, USA</aff>
<aff id="af3-ijms-21-01286"><label>3</label>UC Davis Gene Therapy Program, University of California, Sacramento, CA 95817, USA</aff>
<author-notes>
<corresp id="c1-ijms-21-01286"><label>*</label>Correspondence: <email>wcary@ucdavis.edu</email> (W.C.); <email>janolta@ucdavis.edu</email> (J.A.N.)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<month>2</month>
<year>2020</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<elocation-id>1286</elocation-id>
<history>
<date date-type="received">
<day>11</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 by the authors.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Protein Phosphatase 2 Regulatory Subunit B′ Delta (<italic>PPP2R5D</italic>)-related intellectual disability (ID) and neurodevelopmental delay results from germline de novo mutations in the <italic>PPP2R5D</italic> gene. This gene encodes the protein PPP2R5D (also known as the B56 delta subunit), which is an isoform of the subunit family B56 of the enzyme serine/threonine-protein phosphatase 2A (PP2A). Clinical signs include intellectual disability (ID); autism spectrum disorder (ASD); epilepsy; speech problems; behavioral challenges; and ophthalmologic, skeletal, endocrine, cardiac, and genital malformations. The association of defective PP2A activity in the brain with a wide range of severity of ID, along with its role in ASD, Alzheimer’s disease, and Parkinson’s-like symptoms, have recently generated the impetus for further research into mutations within this gene. PP2A, together with protein phosphatase 1 (PP1), accounts for more than 90% of all phospho-serine/threonine dephosphorylations in different tissues. The specificity for a wide variety of substrates is determined through nearly 100 different PP2A holoenzymes that are formed by at least 23 types of regulatory B subunits, and two isoforms each of the catalytic subunit C and the structural subunit A. In the mammalian brain, PP2A-mediated protein dephosphorylation plays an important role in learning and memory. The PPP2R5D subunit is highly expressed in the brain and the PPP2A–PPP2R5D holoenzyme plays an important role in maintaining neurons and regulating neuronal signaling. From 2015 to 2017, 25 individuals with <italic>PPP2R5D</italic>-related developmental disorder were diagnosed. Since then, Whole-Exome Sequencing (WES) has helped to identify more unrelated individuals clinically diagnosed with a neurodevelopmental disorder with pathological variants of <italic>PPP2R5D</italic>. In this review, we discuss the current understanding of the clinical and genetic aspects of the disorder in the context of the known functions of the PP2A–PPP2R5D holoenzyme in the brain, as well as the pathogenic mutations in <italic>PPP2R5D</italic> that lead to deficient PP2A–PPP2R5D dephosphorylation and their implications during development and in the etiology of autism, Parkinson’s disease, Alzheimer’s disease, and so forth. In the future, tools such as transgenic animals carrying pathogenic PPP2R5D mutations, and patient-derived induced pluripotent stem cell lines need to be developed in order to fully understand the effects of these mutations on different neural cell types.</p>
</abstract>
<kwd-group>
<kwd>autism spectrum disorders</kwd>
<kwd>PPP2R5D</kwd>
<kwd>seizures</kwd>
<kwd>neurodevelopmental disabilities</kwd>
<kwd>phosphatase</kwd>
<kwd>review</kwd>
<kwd>intellectual disability</kwd>
<kwd>PP2A</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijms-21-01286">
<title>1. Background</title>
<p>Protein Phosphatase 2 Regulatory Subunit B′ Delta (<italic>PPP2R5D</italic>)-related intellectual disability (ID) and neurodevelopmental delay is a disorder that mainly occurs due to de novo mutations in the <italic>PPP2R5D</italic> gene [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]. The <italic>PPP2R5D</italic> gene codes for one of the isoforms of the regulatory subunit family B56, of the heteromeric enzyme protein phosphatase 2A (PP2A) [<xref ref-type="bibr" rid="B5-ijms-21-01286">5</xref>]. Mutations in <italic>PPP2R5D</italic> are associated with neurodevelopmental delay, autism spectrum disorder (ASD), ID, behavioral challenges, and so forth, which are seen soon after birth [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. In the United States, this disorder is currently referred to as Jordan’s syndrome, named after Jordan Lang, the first child diagnosed in the United States [<xref ref-type="bibr" rid="B7-ijms-21-01286">7</xref>]. The severity of <italic>PPP2R5D</italic>-mutation-related ID along with the association of PP2A dysfunction with Alzheimer’s disease [<xref ref-type="bibr" rid="B8-ijms-21-01286">8</xref>], Parkinson’s-like symptoms [<xref ref-type="bibr" rid="B9-ijms-21-01286">9</xref>,<xref ref-type="bibr" rid="B10-ijms-21-01286">10</xref>], and cancer [<xref ref-type="bibr" rid="B11-ijms-21-01286">11</xref>,<xref ref-type="bibr" rid="B12-ijms-21-01286">12</xref>] has generated a strong need to study the effects of these mutations on the development and functions of different neural cells.</p>
<p>PP2A is a major serine (Ser)/threonine (Thr) phosphatase family comprising more than 100 holoenzymes (reviewed in [<xref ref-type="bibr" rid="B13-ijms-21-01286">13</xref>]) that performs diverse and substrate-specific physiologic functions in different tissues (reviewed in [<xref ref-type="bibr" rid="B14-ijms-21-01286">14</xref>]). The specificity for a wide variety of tissue-specific substrates is determined through approximately 100 different combinations of the holoenzymes formed by the two A and C isoforms each, along with 23 different isoforms of the B subunits (reviewed in [<xref ref-type="bibr" rid="B8-ijms-21-01286">8</xref>,<xref ref-type="bibr" rid="B14-ijms-21-01286">14</xref>,<xref ref-type="bibr" rid="B15-ijms-21-01286">15</xref>]). PP2A is essential for key cellular processes occurring both during development and in adults, including gene transcription, cell division and growth, and muscle contraction (reviewed in [<xref ref-type="bibr" rid="B11-ijms-21-01286">11</xref>,<xref ref-type="bibr" rid="B13-ijms-21-01286">13</xref>,<xref ref-type="bibr" rid="B14-ijms-21-01286">14</xref>,<xref ref-type="bibr" rid="B16-ijms-21-01286">16</xref>,<xref ref-type="bibr" rid="B17-ijms-21-01286">17</xref>,<xref ref-type="bibr" rid="B18-ijms-21-01286">18</xref>,<xref ref-type="bibr" rid="B19-ijms-21-01286">19</xref>,<xref ref-type="bibr" rid="B20-ijms-21-01286">20</xref>,<xref ref-type="bibr" rid="B21-ijms-21-01286">21</xref>]). De novo mutations within <italic>PPP2R5D</italic> result in defective PP2A–PPP2R5D holoenzyme activities, such as the inability to recognize the substrate or relocate to the nucleus, and deficient catalytic activity [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]. The PPP2R5D protein is highly expressed in the human brain [<xref ref-type="bibr" rid="B22-ijms-21-01286">22</xref>], where the PP2A–PPP2R5D holoenzyme is involved in controlling the activity of signaling pathways that play roles in the maintenance and functioning of neurons (discussed in detail later).</p>
<p>In this review, we report the current understanding of the structure and functions of the PP2A–PPP2R5D holoenzyme, the pathogenic mutations in <italic>PPP2R5D</italic>, and the associated clinical signs of ID and developmental delay. We have also reviewed the current literature on the role of PPP2A–PPP2R5D in different signaling pathways that are relevant in autism spectrum disorder, Alzheimer’s disease 8, and Parkinson’s disease.</p>
</sec>
<sec id="sec2-ijms-21-01286">
<title>2. Genetics</title>
<p>The <italic>PPP2R5D</italic> gene locus is on chromosome 6 in humans and on chromosome 17 in mice [<xref ref-type="bibr" rid="B23-ijms-21-01286">23</xref>]. <italic>PPP2R5D</italic> encodes the 602-amino-acid protein PPP2R5D (also known as the B56δ subunit) [<xref ref-type="bibr" rid="B24-ijms-21-01286">24</xref>]. Both male and female offspring can have the germline pathogenic mutations [<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. In humans, the majority of the pathogenic mutations in this gene are often missense mutations arising de novo during gestation [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>] or may be generated in the family for the first time because of a new variant in germ cells of any one of the parents (or both). In 1996, Del-Mazo’s lab had isolated and cloned a gene initially called Tex271 by differential screening of a subtractive library derived from mouse testis tissue [<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>]. Subsequently, Tex271 was shown to be the mouse <italic>Ppp2r5d</italic> [<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B15-ijms-21-01286">15</xref>].</p>
</sec>
<sec id="sec3-ijms-21-01286">
<title>3. Clinical Signs</title>
<p>The clinical signs of <italic>PPP2R5D</italic>-related disorder include moderate to severe intellectual disability, autism spectrum disorder, and neurodevelopmental delay immediately after birth [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. All patients have a speech impairment [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>], hypotonia [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>], macrocephaly 2, and frontal bossing (protruding forehead) [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. Others have susceptibility to complex partial, generalized, or multifocal epilepsy (epileptic spasms or tonic–clonic); global developmental delay; mild orbital hypertelorism (increased distance between the eyes); delay in gross motor skills; and downslanting palpebral fissures [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. Other clinical signs associated with these mutations include ophthalmologic, skeletal, endocrine, cardiac, and genital abnormalities [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]. The age of affected individuals ranges from 22 months to 53 years [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]. In terms of brain magnetic resonance imaging (MRI) results, all of these individuals present with megalencephaly [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>] and one or more nonspecific MRI findings [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>], such as abnormalities in the white matter, presence of cavum septum pellucidum et vergae and cavum septum pellucidum, small or dysplastic corpus callosum, hydrocephalus, and mild to moderate ventricular dilations [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. Because <italic>PPP2R5D</italic>-related clinical signs can overlap with clinical features of other neurodevelopmental disorders, a differential diagnosis is achieved by combining MRI data along with genetic testing of the proband for pathogenic <italic>PPP2R5D</italic> variants [<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>].</p>
<p>Deletions of the chromosome locus 6p21.1 that contains <italic>PPP2R5D</italic> have been reported in the DECIPHER (DatabasE of genomiC varIation and Phenotype in Humans using Ensembl Resources) databases as being associated with disease [<xref ref-type="bibr" rid="B25-ijms-21-01286">25</xref>]. Two patients with chromosome deletions including all of <italic>PPP2R5D</italic> were reported with similar phenotypes [<xref ref-type="bibr" rid="B25-ijms-21-01286">25</xref>]. Clinical features of the patients included developmental delay, low-set ears, prominent forehead, and a depressed nasal bridge; a third child had intellectual disability, hypotonia, downslanting palpebral fissures, delayed speech and language development, hydrocephalus, and hypotonia [<xref ref-type="bibr" rid="B25-ijms-21-01286">25</xref>]. Another child with gene duplication including part of <italic>PPP2R5D</italic> has been reported with signs of developmental delay [<xref ref-type="bibr" rid="B25-ijms-21-01286">25</xref>].</p>
</sec>
<sec id="sec4-ijms-21-01286">
<title>4. Etiology</title>
<p>PPP2R5D-related disorder is an autosomal dominant condition since one copy of the mutated gene in each cell is sufficient to cause the disorder. From 2015 to 2017, 25 individuals with <italic>PPP2R5D</italic>-related disorders were reported in the published literature [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]. All patients were diagnosed as having <italic>PPP2R5D</italic>-related ID and neurodevelopmental disorder after the identification of a heterozygous pathogenic variant in <italic>PPP2R5D</italic> on molecular genetic testing established in a proband. Since then, Whole-Exome Sequencing (WES) has helped to identify 100 unrelated individuals clinically diagnosed with a neurodevelopmental disorder with 13 variations of the PPP2R5D mutation [<xref ref-type="bibr" rid="B7-ijms-21-01286">7</xref>]. The availability of WES as a part of a newborn genetic disease screening tool is expected to identify many more patients in the future.</p>
</sec>
<sec id="sec5-ijms-21-01286">
<title>5. Tissue Expressions and Functions of the PPP2R5D Subunit</title>
<p>Both the <italic>PPP2R5D</italic> gene and the protein are expressed in most organs during embryonic development in humans [<xref ref-type="bibr" rid="B22-ijms-21-01286">22</xref>]. After birth, it is expressed in many tissues, but the highest expression is seen in the brain 22. In mice, Ppp2r5d is widely expressed in the embryo [<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B26-ijms-21-01286">26</xref>] and postnatally in many tissues, with the highest expression in the brain and spinal cord [<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B5-ijms-21-01286">5</xref>,<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]. Within the mouse brain, the highest Ppp2r5d protein expression is seen in the striatum and thalamus; intermediate expression in the brain stem, CA1, CA2, CA3 regions, and dentate gyrus of the hippocampus; and relatively weak expression is seen in the cortex and cerebellum [<xref ref-type="bibr" rid="B28-ijms-21-01286">28</xref>]. In mammalian somatic cells, PP2A protein has been detected in the cell membrane, cytosol, and nucleus [<xref ref-type="bibr" rid="B5-ijms-21-01286">5</xref>,<xref ref-type="bibr" rid="B26-ijms-21-01286">26</xref>].</p>
<p>The differential localization of PP2A is determined largely in part by the particular isoforms of the B subunit. The PPP2R5D, PPP2R5γ1, and PPP2Rγ3 isoform containing enzymes were detected in the nucleus, while PP2A containing other isoforms (PPP2R5α, PPP2R5β, and PPP2R5ε) were detected in the cytoplasm [<xref ref-type="bibr" rid="B5-ijms-21-01286">5</xref>]. The binding of the PPP2R5D subunit imparts substrate selectivity, intracellular targeting, and catalytic activity [<xref ref-type="bibr" rid="B18-ijms-21-01286">18</xref>]. Both PPP2R5D and another isoform (PPP2R5γ3) share a potential bipartite nuclear localization signal starting at residue 547 of PPP2R5D responsible for the targeting of holoenzyme to the nucleus [<xref ref-type="bibr" rid="B5-ijms-21-01286">5</xref>,<xref ref-type="bibr" rid="B24-ijms-21-01286">24</xref>]. The PP2A–PPP2R5D holoenzyme is also critically involved in the negative regulation of cell growth, remodeling of the chromatin, regulation of transcription, and is a component of the phosphoinositide-3-kinase–protein-kinase-B (PI3K/AKT) growth regulatory cascade [<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>].</p>
</sec>
<sec id="sec6-ijms-21-01286">
<title>6. Pathogenic Mutations in PPP2R5D Leading to Defective PP2A–PPP2R5D Activity</title>
<p>The various single nucleotide substitution mutations in <italic>PPP2R5D</italic> and the associated clinical phenotypes are listed in <xref ref-type="table" rid="ijms-21-01286-t001">Table 1</xref>. Mutations that resulted in changes in the amino acid code and replacement of highly conserved amino acids in the PPP2R5D protein have been found to be strongly associated with neurodevelopmental delay and intellectual disabilities [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. In human chromosome 6, four site-specific guanine (G)  &gt;  adenine (A) substitutions in <italic>PPP2R5D</italic> lead to amino acid substitutions glutamic acid (Glu)420lysine (Lys), Glu200Lys, Glu198Lys, and Glu197Lys, and site-specific substitutions of cytosine (C) &gt; thymidine (T), C &gt; G, and C &gt; adenosine (A) lead to proline (Pro)53serine (Ser), Pro201arginine (Arg), and tryptophan (Trp)207Arg substitutions, respectively [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]. All but one <italic>PPP2R5D</italic> mutation are in a highly conserved acidic loop of the PPP2R5D subunit critical for PP2A–PPP2R5D holoenzyme formation [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]. Notably, all the mutations resulted in the introduction of a positively charged arginine or lysine residue. The only exception is the Pro53Ser mutation. Pro53Ser substitution at the N-terminal domain of PPP2R5D changes the binding capacity of the PP2A–PPP2R5D holoenzyme with substrates [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>].</p>
<p>The severity of the clinical signs of ID and neurodevelopmental delay appears to be correlated with the degree of the biochemical defect in PP2A activity (<xref ref-type="table" rid="ijms-21-01286-t001">Table 1</xref>). For example, a severe form of ID has been seen with Glu198Lys and Glu420Lys mutations (<xref ref-type="table" rid="ijms-21-01286-t001">Table 1</xref>), whereas a relatively milder ID was observed in patients with the Glu197Lys and Glu200Lys mutations [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>,<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. Mechanistically, both Glu200Lys and Glu198Lys substitutions (replacement of negatively charged residues by positively charged residues) impair the subunit-A–subunit-C binding and cause defective PP2A–PPP2R5D-dependent dephosphorylation [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]. However, the milder phenotype suggested that inside the acidic groove formed by the three amino acid residues Glu197, 198, and 200, Glu198 is absolutely critical for the three subunits to interact and bind, while substitutions at Glu200 and Glu197 may not severely inhibit inter-subunit interaction and binding [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]. The Glu420 residue is positioned in close proximity to an active core of the catalytic subunit C and is on the outer surface of the PP2A–PPP2R5D holoenzyme complex [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>,<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]. The reversal of charge (negative to positive) due to Glu420Lys substitution at this site profoundly changes the electrostatic profile of the site that is in close proximity to the active site of the enzyme. This indicates that either disrupting the formation of the holoenzyme or failure of recognition of the substrate has similar effects on defective dephosphorylation.</p>
<p>In vitro, functional expression studies with the human embryonic kidney cell line 293 (HEK293 cells) were done to explore if the subunit interactions were disrupted by the <italic>PPP2R5D</italic> missense mutations [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]. HEK293 cells were transfected with green-fluorescent-protein-tagged wild-type or mutant PPP2R5D subunits and were assayed for subunit–subunit interactions. All ID-associated PPP2R5D variants showed deficient holoenzyme formation (i.e., A- or C-to-PPP2R5D association consistent with a dominant-negative effect) [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]. The only exception was Pro53Ser, as expected [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>].</p>
</sec>
<sec id="sec7-ijms-21-01286">
<title>7. Association of PP2A–PPP2R5D Dysregulation with Overgrowth Syndrome and Associated Intellectual Disability</title>
<p>Overgrowth syndromes are referred to as a group of disorders that are mainly characterized by excessive prenatal and postnatal growth compared with an age-and-sex-matched control group [<xref ref-type="bibr" rid="B2-ijms-21-01286">2</xref>]. Although for most individuals, the direct genetic link to their disorder remains unresolved, several overgrowth-syndrome-associated genes have been reported recently [<xref ref-type="bibr" rid="B19-ijms-21-01286">19</xref>]. Interestingly, many of these genes code for the various proteins of the phosphatidylinositol-4,5-bisphosphate 3-kinase/v-AKT murine thymoma viral oncogene homolog 1 (AKT) growth regulatory pathways [<xref ref-type="bibr" rid="B19-ijms-21-01286">19</xref>]. Multiple studies have shown evidence that the PP2A–PPP2R5D holoenzyme shows specificity for AKT [<xref ref-type="bibr" rid="B18-ijms-21-01286">18</xref>]. Specifically, in certain subcellular compartments, PP2A-B56 can directly dephosphorylate AKT Thr-308 and Ser-473 and inhibit AKT activity [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>,<xref ref-type="bibr" rid="B29-ijms-21-01286">29</xref>]. Since AKT dephosphorylation promotes cellular proliferation and growth, it is thought to be a negative regulator of the PI3K/AKT-mediated growth regulatory cascade. Consequently, aberrant activation of the PI3K/Akt pathway is primarily caused by loss of function of all negative controllers, including PP2A [<xref ref-type="bibr" rid="B30-ijms-21-01286">30</xref>].</p>
<p>Detection of de novo gene mutations by exome sequencing has been highly successful in identifying novel genetic causes of overgrowth syndromes [<xref ref-type="bibr" rid="B31-ijms-21-01286">31</xref>,<xref ref-type="bibr" rid="B32-ijms-21-01286">32</xref>]. Through this method, overgrowth-syndrome-affected patients (from unrelated families) were identified with de novo mutations in the PP2A subunit B family genes, including <italic>PPP2R5D</italic> 2. This was also supported by the evidence that de novo mutations in AKT1 cause Proteus syndrome (MIM 176920), a disorder of asymmetric overgrowth and tissue hyperplasia affecting many organs [<xref ref-type="bibr" rid="B33-ijms-21-01286">33</xref>].</p>
</sec>
<sec id="sec8-ijms-21-01286">
<title>8. Animal Models</title>
<p>Transgenic mice in which the <italic>PPP2R5D</italic> gene was knocked out globally (<italic>PPP2R5D</italic>-KO) have been generated and reported [<xref ref-type="bibr" rid="B34-ijms-21-01286">34</xref>]. Unexpectedly, these mice were found to be viable and fertile, given the high expression of PP2A–PPP2R5D protein in the embryo of wild-type mice [<xref ref-type="bibr" rid="B34-ijms-21-01286">34</xref>] and the fact that the PP2A–PPP2R5D holoenzyme is shown to be a negative regulator of cell division cycle 25C (Cdc25C) phosphatase, which is a key regulator of exit from mitosis during embryonic development [<xref ref-type="bibr" rid="B17-ijms-21-01286">17</xref>]. Specifically, PP2A–PPP2R5D dephosphorylates the Cdc25C Thr138 residue [<xref ref-type="bibr" rid="B17-ijms-21-01286">17</xref>], and how this process still occurred in the PPP2R5D-KO mice is not clear given that no facial malformations or gross growth abnormalities were observed. It was proposed that a functional compensatory mechanism exists for the Cdc25 dephosphorylation since the embryonic fibroblasts derived from the PPP2R5D-KO mice appear to upregulate the expression of Wee1 kinase (Wee1) protein, the Cdc25-opposing kinase [<xref ref-type="bibr" rid="B35-ijms-21-01286">35</xref>]. In the KO mice, no expression of PPP2R5D was seen in the brain and spinal cord as expected, while in the wild-type central nervous system (CNS), the PPP2R5D immunoreactivity was seen partially colocalized with F-actin, microtubules, and tau protein in the neurons. Further, in the KO mice, progressive tau hyperphosphorylation along with marked immunoreactivity for the MC-1-positive tau pre-neurofibrillary tangle conformation (found in AD brain) was seen in the brain stem and the dorsal horn of the cervical spinal cord, but neurofibrillary tangles were absent [<xref ref-type="bibr" rid="B35-ijms-21-01286">35</xref>]. Some defects in learning and memory were also seen in the KOs. The same group also reported that <italic>PPP2R5D</italic>-KO mice spontaneously developed hepatic carcinoma via activation of master regulator of cell cycle entry and proliferative metabolism gene (c-Myc) [<xref ref-type="bibr" rid="B12-ijms-21-01286">12</xref>]. Transgenic mice expressing different pathogenic <italic>PPP2R5D</italic> mutations are being developed in several laboratories (personal communication).</p>
</sec>
<sec id="sec9-ijms-21-01286">
<title>9. Structure of the PP2A Enzyme Complex</title>
<p>The PP2A enzyme complex is composed of three subunits: a 65 kDa structural (scaffolding) subunit A (also known as PR65), a variable/regulatory subunit B, and a 36 kDa catalytic subunit C [<xref ref-type="bibr" rid="B16-ijms-21-01286">16</xref>]. The A subunit tightly associates with the C subunit and provides a scaffolding for binding of subunit B [<xref ref-type="bibr" rid="B36-ijms-21-01286">36</xref>]. Subunit A contains 15 tandem repeats of a 39-residue sequence known as a huntingtin-elongation-A subunit-TOR motif (HEAT). The motif is organized into an elongated L-shaped molecule [<xref ref-type="bibr" rid="B37-ijms-21-01286">37</xref>,<xref ref-type="bibr" rid="B38-ijms-21-01286">38</xref>,<xref ref-type="bibr" rid="B39-ijms-21-01286">39</xref>]. The catalytic subunit C recognizes the HEAT subunit by specific interaction with the conserved sequences of the tandem repeats 11–15, [<xref ref-type="bibr" rid="B40-ijms-21-01286">40</xref>,<xref ref-type="bibr" rid="B41-ijms-21-01286">41</xref>,<xref ref-type="bibr" rid="B42-ijms-21-01286">42</xref>]. The formation of the PP2A core enzyme causes the HEAT repeats 12–15 to significantly bend towards the amino terminus of the scaffolding subunit A [<xref ref-type="bibr" rid="B42-ijms-21-01286">42</xref>]. This conformational rearrangement is critical for its catalytic activity. In eukaryotic cells, the structural subunit A has two isoforms (α and β), which share 86% sequence identity and are ubiquitously expressed [<xref ref-type="bibr" rid="B37-ijms-21-01286">37</xref>]. The regulatory B subunits, on the other hand, have highly variable sequences, and the expression levels of various regulatory subunits are highly variable in different tissues [<xref ref-type="bibr" rid="B14-ijms-21-01286">14</xref>,<xref ref-type="bibr" rid="B16-ijms-21-01286">16</xref>]. In order to bind with specific substrates and catalyze the reaction, the PP2A core enzyme interacts with the various isoforms of the subunit B and forms a holoenzyme. The B subunit contains four subfamilies known as the B (PR55), B′ (B56 or PR61), B″ (PR72), and B″′ (PR93/PR110) subunits, together with approximately 16 known members [<xref ref-type="bibr" rid="B14-ijms-21-01286">14</xref>,<xref ref-type="bibr" rid="B16-ijms-21-01286">16</xref>]. PPP2R5D is the delta isoform of B56.</p>
</sec>
<sec id="sec10-ijms-21-01286">
<title>10. Known Functions of the PP2A–PPP2R5D Holoenzyme </title>
<sec id="sec10dot1-ijms-21-01286">
<title>10.1. Targeting of PP2A to the Nucleus</title>
<p>PPP2R5D (and PPP2R5γ) target the PP2A holoenzyme to the nucleus [<xref ref-type="bibr" rid="B5-ijms-21-01286">5</xref>]. However, the localization of PP2A–PPP2R5D alters during different phases of the cell cycle. During the interphase, it is present both in the nucleus and the cytoplasm, but in cells undergoing meiosis or that have recently exited from mitosis, the enzyme is only detected in the nucleus [<xref ref-type="bibr" rid="B5-ijms-21-01286">5</xref>]. The PPP2R5D protein has been detected and isolated from human erythrocytes, suggesting a non-nuclear localization as well [<xref ref-type="bibr" rid="B5-ijms-21-01286">5</xref>].</p>
<p>It has also been shown that PPP2A–PPP2R5D plays a key role in nuclear targeting of the calcium channel, voltage-dependent, beta 4 subunit (CACNB4), which is an auxiliary subunit associated with the pore-forming subunit voltage-gated calcium channels (VGCCs). VGCCs are heteromeric complexes that generate calcium influx in response to electric signals [<xref ref-type="bibr" rid="B43-ijms-21-01286">43</xref>], thereby regulating gene expression, synaptic vesicle exocytosis, and neuronal excitability [<xref ref-type="bibr" rid="B44-ijms-21-01286">44</xref>,<xref ref-type="bibr" rid="B45-ijms-21-01286">45</xref>]. The cytoplasmic CACNB4 controls the level of VGCC expression at the plasma membrane and its biophysical properties [<xref ref-type="bibr" rid="B46-ijms-21-01286">46</xref>]. In humans, a mutation of CACNB4, leading to truncation of CACNB4 C-terminus, has been associated with juvenile myoclonic epilepsy [<xref ref-type="bibr" rid="B47-ijms-21-01286">47</xref>]. Mechanistic studies done on hippocampal neuronal cultures showed that the epilepsy-causing mutation in the CACNB4 protein resulted in its inability to bind to PPP2R5D and thus prevented translocation of the CACNB4–PP2A–PPP2R5D complex to the nucleus [<xref ref-type="bibr" rid="B48-ijms-21-01286">48</xref>]. Nuclear translocation of CACNB4 complexleads to transcription of several genes, including tyrosine hydroxylase, which is noteworthy due to its link to epilepsy [<xref ref-type="bibr" rid="B48-ijms-21-01286">48</xref>]. It can be speculated here that pathogenic mutations in PPP2R5D leading to defective PP2A–PPP2R5D activity could have the same effect on the nuclear targeting of CACNB4 and contribute to the development of epilepsy in these patients.</p>
</sec>
<sec id="sec10dot2-ijms-21-01286">
<title>10.2. The Role of PPP2A–PPP2R5D in Striatal Dopaminergic Neurotransmission</title>
<p>Dopamine- and cyclic adenosine monophosphate (cAMP)-regulated phosphoprotein (DARPP-32) is a major phosphoprotein with selective expressions at dopaminergic nerve terminals [<xref ref-type="bibr" rid="B49-ijms-21-01286">49</xref>]. The phosphorylation state of DARPP-32 involves a mechanism for integrating information arriving at dopaminoceptive neurons via different neurotransmitters, steroid hormones, neuropeptides, and neuromodulators [<xref ref-type="bibr" rid="B49-ijms-21-01286">49</xref>]. In striatal neurons, the function of the PP2A–PPP2R5D holoenzyme is to regulate dopaminergic neurotransmission via dephosphorylation of Thr-75 of DARPP-32 [<xref ref-type="bibr" rid="B9-ijms-21-01286">9</xref>]. PPP2R5D is first phosphorylated at Ser-566 by a cAMP/protein kinase A (PKA)-dependent pathway [<xref ref-type="bibr" rid="B9-ijms-21-01286">9</xref>]. PPP2R5D phosphorylation by PKA results in an increase in the activity of PP2A–PPP2R5D [<xref ref-type="bibr" rid="B50-ijms-21-01286">50</xref>]. In vivo studies with mouse striatal brain slices showed that PKA-mediated phosphorylation of PPP2R5D occurs in response to the activation of dopamine-1 (D1) receptors [<xref ref-type="bibr" rid="B9-ijms-21-01286">9</xref>]. Once Ser-566 is phosphorylated in PPP2R5D, PP2A–PPP2R5D can dephosphorylate Thr-75, the cyclin-dependent kinase 5 (CDK5) site in DARPP-32 9.</p>
</sec>
<sec id="sec10dot3-ijms-21-01286">
<title>10.3. Role of PP2A–PPP2R5D in Neurotrophic Signaling</title>
<p>Nerve growth factor (NGF) is critical for the promotion of growth and survival of the sensory and sympathetic neurons in mammals, including humans (reviewed in [<xref ref-type="bibr" rid="B51-ijms-21-01286">51</xref>]). The physiological action of NGF is mediated by two NGF receptors: the tropomyosin-related kinase A (TrkA), which is a tyrosine kinase, and the transmembrane glycoprotein, a pan-neurotrophin receptor p75NTR that regulates signaling through trkA [<xref ref-type="bibr" rid="B52-ijms-21-01286">52</xref>]. The PP2A–PPP2R5D holoenzyme has been shown to complex with TrkA in order to dephosphorylate the Ser/Thr residues of NGF to potentiate its tyrosine kinase activity [<xref ref-type="bibr" rid="B20-ijms-21-01286">20</xref>]. Therefore, PP2A–PPP2R5D acts at the receptor level to enhance NGF signaling. In in vitro cultures of PC12 cells, PP2A–PPP2R5D has been shown to enhance NGF signaling through the Akt and Ras-mitogen-activated protein kinase cascades, and it promotes neurogenesis and differentiation [<xref ref-type="bibr" rid="B20-ijms-21-01286">20</xref>]. Therefore, PP2A–PPP2R5D maintains neurotrophin-mediated developmental and survival signaling through the dephosphorylation of inhibitory serine/threonine residues on the TrkA receptor tyrosine kinase [<xref ref-type="bibr" rid="B20-ijms-21-01286">20</xref>].</p>
</sec>
<sec id="sec10dot4-ijms-21-01286">
<title>10.4. Role of PP2A–PPP2R5D in Tau Phosphorylation</title>
<p>Yu et al., 2014 [<xref ref-type="bibr" rid="B8-ijms-21-01286">8</xref>] were the first to characterize the regulatory B-subunit-specific regulation of tau protein phosphorylation. Specifically, the PPP2R5D and PPP2R3A isoforms of the B subunits are involved in the dephosphorylation of the CDK5 substrate proteins. This indicates that these subunits play a role in the tau dephosphorylation signaling process. Transgenic mice, in which the PPP2R5D gene was knocked out, exhibited spatially restricted tauopathy by deregulation of CDK5 and activation of glycogen synthase kinase-3β (GSK3β) [<xref ref-type="bibr" rid="B34-ijms-21-01286">34</xref>]. GSK3β is a tau kinase [<xref ref-type="bibr" rid="B34-ijms-21-01286">34</xref>] and its activation results in tau phosphorylation. The PP2A–PPP2R5D complex also leads to tau phosphorylation indirectly. PPP2R5D dephosphorylates protein kinase B (Akt) at the positions Thr-308 and Ser-473 [<xref ref-type="bibr" rid="B34-ijms-21-01286">34</xref>]. This results in the inhibition of Akt activity and prevents Akt from phosphorylating GSK3β at position Ser-9. This allows GSK3β to be activated [<xref ref-type="bibr" rid="B34-ijms-21-01286">34</xref>]. Additional studies have shown that downregulation of the PPP2R5D subunit expression also corresponds to decreased tau phosphorylation at the amino acid positions Ser-202, Thr-205, Thr-231, and Ser-422, which again supports the notion that the PP2A–PPP2R5D complex can activate GSK3β [<xref ref-type="bibr" rid="B8-ijms-21-01286">8</xref>]. Another PP2A B subunit, PPP2R2A, is thought to be involved in reducing the phosphorylation of the tau protein. Thus, PPP2R2A and PPP2R5D are proposed to work in opposite directions regarding tau phosphorylation homeostasis [<xref ref-type="bibr" rid="B8-ijms-21-01286">8</xref>]. In an AD model cell line (H4-SWE), PPP2R5D-silencing RNA treatment reduced the level of phosphorylation at Thr-231, Ser-202/Thr-205, and Ser-422, indicating that the PP2A–PPP2R5D holoenzyme activates a few tau-specific kinases. The presence of the hyperphosphorylated isoforms of tau in the neurofibrillary tangles is a histopathological hallmark of Alzheimer’s disease (reviewed in [<xref ref-type="bibr" rid="B53-ijms-21-01286">53</xref>]).</p>
<p>Transgenic mice that expressed a dominant-negative mutant form of the catalytic subunit C of PP2A in neurons showed endogenous hyperphosphorylation at two distinct epitopes: the physiological site Ser-202/Thr-205 and the AD-related pathological site Ser-422 [<xref ref-type="bibr" rid="B54-ijms-21-01286">54</xref>]. This study also found activation of the extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) signaling pathway in these mice, suggesting an additional, indirect role of defective PP2A activity in tau hyperphosphorylation, besides the direct dephosphorylation of tau by PP2A. Since PPP2R5D is predominantly expressed in mouse neurons [<xref ref-type="bibr" rid="B34-ijms-21-01286">34</xref>], the role of the PP2A–PPP2R5D holoenzyme can be predicted in the tau hyperphosphorylation seen in these animals.</p>
</sec>
<sec id="sec10dot5-ijms-21-01286">
<title>10.5. Role of the PP2A–PPP2R5D Holoenzyme in the Progression of Cell Cycle</title>
<p>During mitosis, the genetic material is divided equally between two resulting daughter cells in a tightly regulated series of molecular events. In order for the cells to initiate mitosis, the cyclin-dependent kinase Cdk1 is first activated [<xref ref-type="bibr" rid="B55-ijms-21-01286">55</xref>,<xref ref-type="bibr" rid="B56-ijms-21-01286">56</xref>]. The active form of the cyclin-dependent kinases, in general, phosphorylate their substrates by transferring the phosphate groups from ATP to specific amino acid residues in the substrates. However, during the interphase, the activity of Cdk1 is repressed by inhibitory phosphorylation of the threonine-14 and tyrosine-15 residues [<xref ref-type="bibr" rid="B55-ijms-21-01286">55</xref>,<xref ref-type="bibr" rid="B56-ijms-21-01286">56</xref>]. This is catalyzed by the actions of the two inhibitory kinases, namely, Wee1 and the Myt1 kinases [<xref ref-type="bibr" rid="B55-ijms-21-01286">55</xref>,<xref ref-type="bibr" rid="B56-ijms-21-01286">56</xref>]. During the G2/M transition, the active form of the phosphatase Cdc25C removes these phosphoryl groups, thus activating Cdk1/cyclin B again [<xref ref-type="bibr" rid="B57-ijms-21-01286">57</xref>]. The exit from mitosis requires the inactivation of Cdk1/cyclin B initiated by the ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C) and its coactivator cell division cycle 20 (CDC20), which causes proteasomal degradation of cyclin B [<xref ref-type="bibr" rid="B58-ijms-21-01286">58</xref>]. Failure to inactivate the Cdk1/cyclin B and degrade cyclin B results in the arrest of the metaphase [<xref ref-type="bibr" rid="B59-ijms-21-01286">59</xref>,<xref ref-type="bibr" rid="B60-ijms-21-01286">60</xref>]. PP2A seems to plays an important role in mitosis because Cdk1/cyclin B inactivation has been shown to depend on an okadaic-acid-sensitive phosphatase (during the metaphase–anaphase transition) [<xref ref-type="bibr" rid="B61-ijms-21-01286">61</xref>]. Okadaic acid is shown to be a potent inhibitor of the serine/threonine protein phosphatases PP1 and PP2A. Also, the PP2A–PPP2R5D holoenzyme complex is a negative regulator of Cdc25C during the interphase. It dephosphorylates Cdc25C threonine/threonine-130 and allows cytosolic sequestration of Cdc25C [<xref ref-type="bibr" rid="B17-ijms-21-01286">17</xref>].</p>
</sec>
</sec>
<sec id="sec11-ijms-21-01286">
<title>11. Future Research</title>
<p>Different neuronal cell types are currently being derived by our team and others from induced pluripotent stem cells (iPSC) generated from individuals diagnosed with PPP2R5D-related developmental delay and ID. These neuronal cell phenotypes would have to be characterized, and any aberrant phosphorylation needs to be characterized. These cells will then be used as a platform for screening small molecules or known drugs.</p>
<p>Transgenic mice carrying pathogenic mutations in <italic>PPP2R5D</italic> are currently being developed. These models can be used to investigate tissue-specific defects in dephosphorylation activity in vivo and to screen for potential drugs and gene therapies. The 3D conformation (structure) of PP2A in complex with PPP2R5D-mutated subunits should be generated in order to map protein–protein interactions. Additionally, the genes PPP2R1A and PPP2R5C, which are closely related to PP2R5D, should also be investigated in detail since they are involved in common pathways. A few individuals with mutations in these genes have been diagnosed; however, with WES testing, more will be detected.</p>
<p>The PP2As are the major serine/threonine phosphatases in all tissues. Thus, the specific substrates for the isoforms still need to be characterized in vivo, particularly in the brain. Isoform-specific antibodies specifically against the PP2A–PPP2R5D isoform as well as isoform-specific small-molecule inhibitors/activators and bioassays need to be developed. These tools will facilitate the progress of elucidating the role of PP2A–PPP2R5D and its therapeutic modulations in the context of ID.</p>
</sec>
<sec id="sec12-ijms-21-01286" sec-type="conclusions">
<title>12. Conclusions</title>
<p>There is currently no cure for ID associated with <italic>PPP2R5D</italic> mutations, but symptoms can be managed, and the treatment of manifestations is the standard treatment for visual impairments, seizures, and developmental delays [<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]. Gene therapy approaches are being studied in order to potentially have a future therapeutic effect for this mutation. Since this disorder was only recently discovered and diagnosed correctly, there is much more to research and learn about this rare and debilitating disorder. Other challenges include incorrect diagnosis by professionals as a result of the fact that the PPP2R5D-related neurodevelopmental and intellectual disability has a nonspecific phenotype and can present as different diseases (or solely as autism spectrum disorders). Genetic testing is needed for an accurate diagnosis.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>Through Jordan’s Guardian Angels, the foundation established by a patient’s family, an international team of clinicians and scientists (including J.N.) have been collaborating on research since 2017.</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>D.B., who is a member of the SPARK training program funded by the California Institute for Regenerative Medicine, researched the topic and wrote the article. W.C. and J.A.N. gave critical feedback and edited the manuscript. All authors have read and agreed to the published version of the manuscript.</p>
</notes>
<notes>
<title>Funding</title>
<p>This research received no external funding.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<glossary>
<title>Abbreviations</title>
<array orientation="portrait">
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PPP2R5D</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein Phosphatase 2 Regulatory Subunit B′ Delta</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PPP2A</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein Phosphatase 2A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MRI</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Magnetic resonance imaging</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PI3K/AKT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Phosphoinositide 3-kinases/ Protein kinase B</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HEAT</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Huntingtin-elongation-A subunit-TOR motif</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">DARPP-32</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Dopamine-regulated neuronal phosphoprotein-32</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">GSK3β</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Glycogen synthase kinase-3β</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cdc25C</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cell division cycle25C</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ADA 3</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Transcriptional adaptor protein 3</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PPP1R1B</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Protein Phosphatase 1 Regulatory Inhibitor Subunit 1B</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">NGF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Nerve growth factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">AD</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Alzheimer disease</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">MPF</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Maturation-promoting factor</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">PC-12 cells</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Pheochromocytoma cell line 12</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Myt1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Myelin Transcription Factor 1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Thr</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Threonine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Ser</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Serine</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">HEK293</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Human embryonic kidney cell line 293</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">TrkA</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Tropomyosin receptor kinase A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Wee1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Wee1 kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ID</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Intellectual disability</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cdk1</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cyclin-dependent kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">Cdc20</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Cell division cycle 20</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">ERK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">Extracellular signal-regulated kinase</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="middle">JNK</td>
<td align="left" colspan="1" rowspan="1" valign="middle">c-Jun N-terminal kinase</td>
</tr>
</tbody>
</array>
</glossary>
<ref-list>
<title>References</title>
<ref id="B1-ijms-21-01286">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Houge</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Haesen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Vissers</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Mehta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vogt</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McKee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tolmie</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Cordeiro</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>B56delta-related protein phosphatase 2A dysfunction identified in patients with intellectual disability</article-title>
<source/>J. Clin. Investig.
          <year>2015</year>
<volume>125</volume>
<fpage>3051</fpage>
<lpage>3062</lpage>
<pub-id pub-id-type="doi">10.1172/JCI79860</pub-id>
<pub-id pub-id-type="pmid">26168268</pub-id>
</element-citation>
</ref>
<ref id="B2-ijms-21-01286">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loveday</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tatton-Brown</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Westwood</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Renwick</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ramsay</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nemeth</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Joss</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth</article-title>
<source/>Hum. Mol. Genet.
          <year>2015</year>
<volume>24</volume>
<fpage>4775</fpage>
<lpage>4779</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddv182</pub-id>
<pub-id pub-id-type="pmid">25972378</pub-id>
</element-citation>
</ref>
<ref id="B3-ijms-21-01286">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>M.T.</given-names>
</name>
<name>
<surname>Petrey</surname>
<given-names>D.S.</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>C.T.</given-names>
</name>
<name>
<surname>Haude</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Shur</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lundberg</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hauser</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Carmichael</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo missense variants in PPP2R5D are associated with intellectual disability, macrocephaly, hypotonia, and autism</article-title>
<source/>Neurogenetics
          <year>2016</year>
<volume>17</volume>
<fpage>43</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1007/s10048-015-0466-9</pub-id>
<pub-id pub-id-type="pmid">26576547</pub-id>
</element-citation>
</ref>
<ref id="B4-ijms-21-01286">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeung</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Tso</surname>
<given-names>W.W.Y.</given-names>
</name>
<name>
<surname>Ip</surname>
<given-names>J.J.K.</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>C.C.Y.</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>G.K.C.</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>M.H.Y.</given-names>
</name>
<name>
<surname>Ying</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>S.L.C.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of mutations in the PI3K-AKT-mTOR signalling pathway in patients with macrocephaly and developmental delay and/or autism</article-title>
<source/>Mol. Autism
          <year>2017</year>
<volume>8</volume>
<fpage>66</fpage>
<pub-id pub-id-type="doi">10.1186/s13229-017-0182-4</pub-id>
<pub-id pub-id-type="pmid">29296277</pub-id>
</element-citation>
</ref>
<ref id="B5-ijms-21-01286">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCright</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Rivers</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Audlin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>The B56 family of protein phosphatase 2A (PP2A) regulatory subunits encodes differentiation-induced phosphoproteins that target PP2A to both nucleus and cytoplasm</article-title>
<source/>J. Biol. Chem.
          <year>1996</year>
<volume>271</volume>
<fpage>22081</fpage>
<lpage>22089</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.271.36.22081</pub-id>
<pub-id pub-id-type="pmid">8703017</pub-id>
</element-citation>
</ref>
<ref id="B6-ijms-21-01286">
<label>6.</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Mirzaa</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Foss</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Nattakom</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>W.K.</given-names>
</name>
</person-group>
<article-title>PPP2R5D-Related Neurodevelopmental Disorder</article-title>
<source/>GeneReviews<sup>®</sup>
<person-group person-group-type="editor">
<name>
<surname>Adam</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Ardinger</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Pagon</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Bean</surname>
<given-names>L.J.H.</given-names>
</name>
<name>
<surname>Stephens</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Amemiya</surname>
<given-names>A.</given-names>
</name>
</person-group>
<publisher-name>University of Washington</publisher-name>
<publisher-loc>Seattle, WA, USA</publisher-loc>
<year>2019</year>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK536360/">https://www.ncbi.nlm.nih.gov/books/NBK536360/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2020-02-10">(accessed on 10 February 2020)</date-in-citation>
</element-citation>
</ref>
<ref id="B7-ijms-21-01286">
<label>7.</label>
<element-citation publication-type="web">
<article-title>Jordan’s Guardian Angels</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://jordansguardianangels.org/the-history-of-jordans-syndrome/">https://jordansguardianangels.org/the-history-of-jordans-syndrome/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2020-02-10">(accessed on 10 February 2020)</date-in-citation>
</element-citation>
</ref>
<ref id="B8-ijms-21-01286">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>U.Y.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>B.C.</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>J.H.</given-names>
</name>
</person-group>
<article-title>Regulatory B Subunits of Protein Phosphatase 2A Are Involved in Site-specific Regulation of Tau Protein Phosphorylation</article-title>
<source/>Korean J. Physiol. Pharmacol.
          <year>2014</year>
<volume>18</volume>
<fpage>155</fpage>
<lpage>161</lpage>
<pub-id pub-id-type="doi">10.4196/kjpp.2014.18.2.155</pub-id>
<pub-id pub-id-type="pmid">24757378</pub-id>
</element-citation>
</ref>
<ref id="B9-ijms-21-01286">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahn</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>McAvoy</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rakhilin</surname>
<given-names>S.V.</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Greengard</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nairn</surname>
<given-names>A.C.</given-names>
</name>
</person-group>
<article-title>Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56delta subunit</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2007</year>
<volume>104</volume>
<fpage>2979</fpage>
<lpage>2984</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0611532104</pub-id>
<pub-id pub-id-type="pmid">17301223</pub-id>
</element-citation>
</ref>
<ref id="B10-ijms-21-01286">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tadmouri</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kiyonaka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barbado</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rousset</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fablet</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Sawamura</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bahembera</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pernet-Gallay</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Arnoult</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Miki</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Cacnb4 directly couples electrical activity to gene expression, a process defective in juvenile epilepsy</article-title>
<source/>EMBO J.
          <year>2012</year>
<volume>31</volume>
<fpage>3730</fpage>
<lpage>3744</lpage>
<pub-id pub-id-type="doi">10.1038/emboj.2012.226</pub-id>
<pub-id pub-id-type="pmid">22892567</pub-id>
</element-citation>
</ref>
<ref id="B11-ijms-21-01286">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eichhorn</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Creyghton</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>Bernards</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Protein phosphatase 2A regulatory subunits and cancer</article-title>
<source/>Biochim. Biophys. Acta
          <year>2009</year>
<volume>1795</volume>
<fpage>1</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbcan.2008.05.005</pub-id>
<pub-id pub-id-type="pmid">18588945</pub-id>
</element-citation>
</ref>
<ref id="B12-ijms-21-01286">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lambrecht</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Libbrecht</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Sagaert</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Pauwels</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hoorne</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Crowther</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Sents</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sablina</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Loss of protein phosphatase 2A regulatory subunit B56delta promotes spontaneous tumorigenesis in vivo</article-title>
<source/>Oncogene
          <year>2018</year>
<volume>37</volume>
<fpage>544</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2017.350</pub-id>
<pub-id pub-id-type="pmid">28967903</pub-id>
</element-citation>
</ref>
<ref id="B13-ijms-21-01286">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zolnierowicz</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Type 2A protein phosphatase, the complex regulator of numerous signaling pathways</article-title>
<source/>Biochem. Pharmacol.
          <year>2000</year>
<volume>60</volume>
<fpage>1225</fpage>
<lpage>1235</lpage>
<pub-id pub-id-type="doi">10.1016/S0006-2952(00)00424-X</pub-id>
<pub-id pub-id-type="pmid">11007961</pub-id>
</element-citation>
</ref>
<ref id="B14-ijms-21-01286">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lechward</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Awotunde</surname>
<given-names>O.S.</given-names>
</name>
<name>
<surname>Swiatek</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Muszynska</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Protein phosphatase 2A: Variety of forms and diversity of functions</article-title>
<source/>Acta Biochim. Pol.
          <year>2001</year>
<volume>48</volume>
<fpage>921</fpage>
<lpage>933</lpage>
<pub-id pub-id-type="doi">10.18388/abp.2001_3858</pub-id>
<pub-id pub-id-type="pmid">11996003</pub-id>
</element-citation>
</ref>
<ref id="B15-ijms-21-01286">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csortos</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zolnierowicz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bako</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Durbin</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>DePaoli-Roach</surname>
<given-names>A.A.</given-names>
</name>
</person-group>
<article-title>High complexity in the expression of the B′ subunit of protein phosphatase 2A0. Evidence for the existence of at least seven novel isoforms</article-title>
<source/>J. Biol. Chem.
          <year>1996</year>
<volume>271</volume>
<fpage>2578</fpage>
<lpage>2588</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.271.5.2578</pub-id>
<pub-id pub-id-type="pmid">8576224</pub-id>
</element-citation>
</ref>
<ref id="B16-ijms-21-01286">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janssens</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Goris</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Van Hoof</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>PP2A: The expected tumor suppressor</article-title>
<source/>Curr. Opin. Genet. Dev.
          <year>2005</year>
<volume>15</volume>
<fpage>34</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.gde.2004.12.004</pub-id>
<pub-id pub-id-type="pmid">15661531</pub-id>
</element-citation>
</ref>
<ref id="B17-ijms-21-01286">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Margolis</surname>
<given-names>S.S.</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Forester</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Nutt</surname>
<given-names>L.K.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jardim</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Thomenius</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Freel</surname>
<given-names>C.D.</given-names>
</name>
<name>
<surname>Darbandi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ahn</surname>
<given-names>J.H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role for the PP2A/B56delta phosphatase in regulating 14-3-3 release from Cdc25 to control mitosis</article-title>
<source/>Cell
          <year>2006</year>
<volume>127</volume>
<fpage>759</fpage>
<lpage>773</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.10.035</pub-id>
<pub-id pub-id-type="pmid">17110335</pub-id>
</element-citation>
</ref>
<ref id="B18-ijms-21-01286">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seshacharyulu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Datta</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Batra</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer</article-title>
<source/>Cancer Lett.
          <year>2013</year>
<volume>335</volume>
<fpage>9</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2013.02.036</pub-id>
<pub-id pub-id-type="pmid">23454242</pub-id>
</element-citation>
</ref>
<ref id="B19-ijms-21-01286">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatton-Brown</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Weksberg</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Molecular mechanisms of childhood overgrowth</article-title>
<source/>Am. J. Med. Genet. C Semin. Med. Genet.
          <year>2013</year>
<volume>163c</volume>
<fpage>71</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.c.31362</pub-id>
<pub-id pub-id-type="pmid">23606607</pub-id>
</element-citation>
</ref>
<ref id="B20-ijms-21-01286">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Kanegan</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Strack</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>The Protein Phosphatase 2A Regulatory Subunits B′β and B′δ Mediate Sustained TrkA Neurotrophin Receptor Autophosphorylation and Neuronal Differentiation</article-title>
<source/>Mol. Cell. Biol.
          <year>2009</year>
<volume>29</volume>
<fpage>662</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01242-08</pub-id>
<pub-id pub-id-type="pmid">19029245</pub-id>
</element-citation>
</ref>
<ref id="B21-ijms-21-01286">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Phiel</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Functions of B56-containing PP2As in major developmental and cancer signaling pathways</article-title>
<source/>Life Sci.
          <year>2010</year>
<volume>87</volume>
<fpage>659</fpage>
<lpage>666</lpage>
<pub-id pub-id-type="doi">10.1016/j.lfs.2010.10.003</pub-id>
<pub-id pub-id-type="pmid">20934435</pub-id>
</element-citation>
</ref>
<ref id="B22-ijms-21-01286">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uhlen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fagerberg</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hallstrom</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Lindskog</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Oksvold</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mardinoglu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sivertsson</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kampf</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sjostedt</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Asplund</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Proteomics. Tissue-based map of the human proteome</article-title>
<source/>Science
          <year>2015</year>
<volume>347</volume>
<fpage>1260419</fpage>
<pub-id pub-id-type="doi">10.1126/science.1260419</pub-id>
<pub-id pub-id-type="pmid">25613900</pub-id>
</element-citation>
</ref>
<ref id="B23-ijms-21-01286">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohinata</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sutou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kondo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mitsui</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Male-enhanced antigen-1 gene flanked by two overlapping genes is expressed in late spermatogenesis</article-title>
<source/>Biol. Reprod.
          <year>2002</year>
<volume>67</volume>
<fpage>1824</fpage>
<lpage>1831</lpage>
<pub-id pub-id-type="doi">10.1095/biolreprod.101.002550</pub-id>
<pub-id pub-id-type="pmid">12444059</pub-id>
</element-citation>
</ref>
<ref id="B24-ijms-21-01286">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCright</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Brothman</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Assignment of human protein phosphatase 2A regulatory subunit genes b56alpha, b56beta, b56gamma, b56delta, and b56epsilon (PPP2R5A-PPP2R5E), highly expressed in muscle and brain, to chromosome regions 1q41, 11q12, 3p21, 6p21.1, and 7p11.2 --&gt; p12</article-title>
<source/>Genomics
          <year>1996</year>
<volume>36</volume>
<fpage>168</fpage>
<lpage>170</lpage>
<pub-id pub-id-type="doi">10.1006/geno.1996.0438</pub-id>
<pub-id pub-id-type="pmid">8812429</pub-id>
</element-citation>
</ref>
<ref id="B25-ijms-21-01286">
<label>25.</label>
<element-citation publication-type="web">
<article-title>DECIPHER</article-title>
<comment>Available online: <ext-link ext-link-type="uri" xlink:href="https://decipher.sanger.ac.uk/">https://decipher.sanger.ac.uk/</ext-link></comment>
<date-in-citation content-type="access-date" iso-8601-date="2020-02-10">(accessed on 10 February 2020)</date-in-citation>
</element-citation>
</ref>
<ref id="B26-ijms-21-01286">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turowski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Favre</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Lamb</surname>
<given-names>N.J.</given-names>
</name>
<name>
<surname>Hemmings</surname>
<given-names>B.A.</given-names>
</name>
</person-group>
<article-title>Differential methylation and altered conformation of cytoplasmic and nuclear forms of protein phosphatase 2A during cell cycle progression</article-title>
<source/>J. Cell. Biol.
          <year>1995</year>
<volume>129</volume>
<fpage>397</fpage>
<lpage>410</lpage>
<pub-id pub-id-type="doi">10.1083/jcb.129.2.397</pub-id>
<pub-id pub-id-type="pmid">7721943</pub-id>
</element-citation>
</ref>
<ref id="B27-ijms-21-01286">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rocher</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Letourneux</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lenormand</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Porteu</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity</article-title>
<source/>J. Biol. Chem.
          <year>2007</year>
<volume>282</volume>
<fpage>5468</fpage>
<lpage>5477</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M609712200</pub-id>
<pub-id pub-id-type="pmid">17200115</pub-id>
</element-citation>
</ref>
<ref id="B28-ijms-21-01286">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martens</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Janssens</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Vermeesch</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gotz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Goris</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Van Hoof</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Genomic organisation, chromosomal localisation tissue distribution and developmental regulation of the PR61/B′ regulatory subunits of protein phosphatase 2A in mice</article-title>
<source/>J. Mol. Biol.
          <year>2004</year>
<volume>336</volume>
<fpage>971</fpage>
<lpage>986</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2003.12.047</pub-id>
<pub-id pub-id-type="pmid">15095873</pub-id>
</element-citation>
</ref>
<ref id="B29-ijms-21-01286">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodgers</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Vogel</surname>
<given-names>R.O.</given-names>
</name>
<name>
<surname>Puigserver</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Clk2 and B56beta mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt</article-title>
<source/>Mol. Cell.
          <year>2011</year>
<volume>41</volume>
<fpage>471</fpage>
<lpage>479</lpage>
<pub-id pub-id-type="doi">10.1016/j.molcel.2011.02.007</pub-id>
<pub-id pub-id-type="pmid">21329884</pub-id>
</element-citation>
</ref>
<ref id="B30-ijms-21-01286">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Claret</surname>
<given-names>F.X.</given-names>
</name>
</person-group>
<article-title>Phosphatases: The new brakes for cancer development?</article-title>
<source/>Enzyme Res.
          <year>2012</year>
<volume>2012</volume>
<fpage>659649</fpage>
<pub-id pub-id-type="doi">10.1155/2012/659649</pub-id>
<pub-id pub-id-type="pmid">22121480</pub-id>
</element-citation>
</ref>
<ref id="B31-ijms-21-01286">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatton-Brown</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hanks</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ruark</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zachariou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Duarte Sdel</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Ramsay</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Snape</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Perdeaux</surname>
<given-names>E.R.</given-names>
</name>
<name>
<surname>Seal</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Germline mutations in the oncogene EZH2 cause Weaver syndrome and increased human height</article-title>
<source/>Oncotarget
          <year>2011</year>
<volume>2</volume>
<fpage>1127</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.385</pub-id>
<pub-id pub-id-type="pmid">22190405</pub-id>
</element-citation>
</ref>
<ref id="B32-ijms-21-01286">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tatton-Brown</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Seal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ruark</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Harmer</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ramsay</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Del Vecchio Duarte</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zachariou</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hanks</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Aksglaede</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mutations in the DNA methyltransferase gene DNMT3A cause an overgrowth syndrome with intellectual disability</article-title>
<source/>Nat. Genet.
          <year>2014</year>
<volume>46</volume>
<fpage>385</fpage>
<lpage>388</lpage>
<pub-id pub-id-type="doi">10.1038/ng.2917</pub-id>
<pub-id pub-id-type="pmid">24614070</pub-id>
</element-citation>
</ref>
<ref id="B33-ijms-21-01286">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lindhurst</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Sapp</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Teer</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Finn</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cannons</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Bick</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Blakemore</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A mosaic activating mutation in AKT1 associated with the Proteus syndrome</article-title>
<source/>N. Engl. J. Med.
          <year>2011</year>
<volume>365</volume>
<fpage>611</fpage>
<lpage>619</lpage>
<pub-id pub-id-type="doi">10.1056/NEJMoa1104017</pub-id>
<pub-id pub-id-type="pmid">21793738</pub-id>
</element-citation>
</ref>
<ref id="B34-ijms-21-01286">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Louis</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Martens</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Borghgraef</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Lambrecht</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sents</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Longin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zwaenepoel</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pijnenborg</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Landrieu</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Lippens</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mice lacking phosphatase PP2A subunit PR61/B′delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2011</year>
<volume>108</volume>
<fpage>6957</fpage>
<lpage>6962</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1018777108</pub-id>
<pub-id pub-id-type="pmid">21482799</pub-id>
</element-citation>
</ref>
<ref id="B35-ijms-21-01286">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forester</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Maddox</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Louis</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Goris</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Virshup</surname>
<given-names>D.M.</given-names>
</name>
</person-group>
<article-title>Control of mitotic exit by PP2A regulation of Cdc25C and Cdk1</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>2007</year>
<volume>104</volume>
<fpage>19867</fpage>
<lpage>19872</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0709879104</pub-id>
<pub-id pub-id-type="pmid">18056802</pub-id>
</element-citation>
</ref>
<ref id="B36-ijms-21-01286">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Pham</surname>
<given-names>H.T.</given-names>
</name>
<name>
<surname>Ruediger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Characterization of the Aalpha and Abeta subunit isoforms of protein phosphatase 2A: Differences in expression, subunit interaction, and evolution</article-title>
<source/>Biochem. J.
          <year>2003</year>
<volume>369</volume>
<fpage>387</fpage>
<lpage>398</lpage>
<pub-id pub-id-type="doi">10.1042/bj20021244</pub-id>
<pub-id pub-id-type="pmid">12370081</pub-id>
</element-citation>
</ref>
<ref id="B37-ijms-21-01286">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hemmings</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Adams-Pearson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Maurer</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Goris</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Merlevede</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hofsteenge</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>S.R.</given-names>
</name>
</person-group>
<article-title>alpha- and beta-forms of the 65-kDa subunit of protein phosphatase 2A have a similar 39 amino acid repeating structure</article-title>
<source/>Biochemistry
          <year>1990</year>
<volume>29</volume>
<fpage>3166</fpage>
<lpage>3173</lpage>
<pub-id pub-id-type="doi">10.1021/bi00465a002</pub-id>
<pub-id pub-id-type="pmid">2159327</pub-id>
</element-citation>
</ref>
<ref id="B38-ijms-21-01286">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walter</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ferre</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Espiritu</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Carbone-Wiley</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Molecular cloning and sequence of cDNA encoding polyoma medium tumor antigen-associated 61-kDa protein</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1989</year>
<volume>86</volume>
<fpage>8669</fpage>
<lpage>8672</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.86.22.8669</pub-id>
<pub-id pub-id-type="pmid">2554323</pub-id>
</element-citation>
</ref>
<ref id="B39-ijms-21-01286">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groves</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Hanlon</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Turowski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hemmings</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Barford</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>The structure of the protein phosphatase 2A PR65/A subunit reveals the conformation of its 15 tandemly repeated HEAT motifs</article-title>
<source/>Cell
          <year>1999</year>
<volume>96</volume>
<fpage>99</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1016/S0092-8674(00)80963-0</pub-id>
<pub-id pub-id-type="pmid">9989501</pub-id>
</element-citation>
</ref>
<ref id="B40-ijms-21-01286">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruediger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Hentz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fait</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mumby</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Molecular model of the A subunit of protein phosphatase 2A: Interaction with other subunits and tumor antigens</article-title>
<source/>J. Virol.
          <year>1994</year>
<volume>68</volume>
<fpage>123</fpage>
<lpage>129</lpage>
<pub-id pub-id-type="doi">10.1128/JVI.68.1.123-129.1994</pub-id>
<pub-id pub-id-type="pmid">8254721</pub-id>
</element-citation>
</ref>
<ref id="B41-ijms-21-01286">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ruediger</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Roeckel</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Fait</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bergqvist</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Magnusson</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Walter</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Identification of binding sites on the regulatory A subunit of protein phosphatase 2A for the catalytic C subunit and for tumor antigens of simian virus 40 and polyomavirus</article-title>
<source/>Mol. Cell. Biol.
          <year>1992</year>
<volume>12</volume>
<fpage>4872</fpage>
<lpage>4882</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.12.11.4872</pub-id>
<pub-id pub-id-type="pmid">1328865</pub-id>
</element-citation>
</ref>
<ref id="B42-ijms-21-01286">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xing</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jeffrey</surname>
<given-names>P.D.</given-names>
</name>
<name>
<surname>Chao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Strack</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stock</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Structure of protein phosphatase 2A core enzyme bound to tumor-inducing toxins</article-title>
<source/>Cell
          <year>2006</year>
<volume>127</volume>
<fpage>341</fpage>
<lpage>353</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2006.09.025</pub-id>
<pub-id pub-id-type="pmid">17055435</pub-id>
</element-citation>
</ref>
<ref id="B43-ijms-21-01286">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catterall</surname>
<given-names>W.A.</given-names>
</name>
<name>
<surname>Perez-Reyes</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Snutch</surname>
<given-names>T.P.</given-names>
</name>
<name>
<surname>Striessnig</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels</article-title>
<source/>Pharmacol. Rev.
          <year>2005</year>
<volume>57</volume>
<fpage>411</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1124/pr.57.4.5</pub-id>
<pub-id pub-id-type="pmid">16382099</pub-id>
</element-citation>
</ref>
<ref id="B44-ijms-21-01286">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deisseroth</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mermelstein</surname>
<given-names>P.G.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tsien</surname>
<given-names>R.W.</given-names>
</name>
</person-group>
<article-title>Signaling from synapse to nucleus: The logic behind the mechanisms</article-title>
<source/>Curr. Opin. Neurobiol.
          <year>2003</year>
<volume>13</volume>
<fpage>354</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="doi">10.1016/S0959-4388(03)00076-X</pub-id>
<pub-id pub-id-type="pmid">12850221</pub-id>
</element-citation>
</ref>
<ref id="B45-ijms-21-01286">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flavell</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>M.E.</given-names>
</name>
</person-group>
<article-title>Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system</article-title>
<source/>Annu. Rev. Neurosci.
          <year>2008</year>
<volume>31</volume>
<fpage>563</fpage>
<lpage>590</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.neuro.31.060407.125631</pub-id>
<pub-id pub-id-type="pmid">18558867</pub-id>
</element-citation>
</ref>
<ref id="B46-ijms-21-01286">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arikkath</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>K.P.</given-names>
</name>
</person-group>
<article-title>Auxiliary subunits: Essential components of the voltage-gated calcium channel complex</article-title>
<source/>Curr. Opin. Neurobiol.
          <year>2003</year>
<volume>13</volume>
<fpage>298</fpage>
<lpage>307</lpage>
<pub-id pub-id-type="doi">10.1016/S0959-4388(03)00066-7</pub-id>
<pub-id pub-id-type="pmid">12850214</pub-id>
</element-citation>
</ref>
<ref id="B47-ijms-21-01286">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Escayg</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De Waard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D.D.</given-names>
</name>
<name>
<surname>Bichet</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mayer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Baloh</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Meisler</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia</article-title>
<source/>Am. J. Hum. Genet.
          <year>2000</year>
<volume>66</volume>
<fpage>1531</fpage>
<lpage>1539</lpage>
<pub-id pub-id-type="doi">10.1086/302909</pub-id>
<pub-id pub-id-type="pmid">10762541</pub-id>
</element-citation>
</ref>
<ref id="B48-ijms-21-01286">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ronjat</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kiyonaka</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barbado</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>De Waard</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mori</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Nuclear life of the voltage-gated Cacnb4 subunit and its role in gene transcription regulation</article-title>
<source/>Channels
          <year>2013</year>
<volume>7</volume>
<fpage>119</fpage>
<lpage>125</lpage>
<pub-id pub-id-type="doi">10.4161/chan.23895</pub-id>
<pub-id pub-id-type="pmid">23511121</pub-id>
</element-citation>
</ref>
<ref id="B49-ijms-21-01286">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svenningsson</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nishi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Fisone</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Girault</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Nairn</surname>
<given-names>A.C.</given-names>
</name>
<name>
<surname>Greengard</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>DARPP-32: An integrator of neurotransmission</article-title>
<source/>Annu. Rev. Pharmacol. Toxicol.
          <year>2004</year>
<volume>44</volume>
<fpage>269</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.pharmtox.44.101802.121415</pub-id>
<pub-id pub-id-type="pmid">14744247</pub-id>
</element-citation>
</ref>
<ref id="B50-ijms-21-01286">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Usui</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tanabe</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Nishito</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kagamiyama</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Takeda</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Activation of protein phosphatase 2A by cAMP-dependent protein kinase-catalyzed phosphorylation of the 74-kDa B′′ (delta) regulatory subunit in virto and identification of the phosphorylation sites</article-title>
<source/>FEBS Lett.
          <year>1998</year>
<volume>430</volume>
<fpage>312</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="doi">10.1016/S0014-5793(98)00684-X</pub-id>
<pub-id pub-id-type="pmid">9688562</pub-id>
</element-citation>
</ref>
<ref id="B51-ijms-21-01286">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levi-Montalcini</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>The nerve growth factor 35 years later</article-title>
<source/>Science
          <year>1987</year>
<volume>237</volume>
<fpage>1154</fpage>
<lpage>1162</lpage>
<pub-id pub-id-type="doi">10.1126/science.3306916</pub-id>
<pub-id pub-id-type="pmid">3306916</pub-id>
</element-citation>
</ref>
<ref id="B52-ijms-21-01286">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Reichardt</surname>
<given-names>L.F.</given-names>
</name>
</person-group>
<article-title>Trk receptors: Roles in neuronal signal transduction</article-title>
<source/>Annu. Rev. Biochem.
          <year>2003</year>
<volume>72</volume>
<fpage>609</fpage>
<lpage>642</lpage>
<pub-id pub-id-type="doi">10.1146/annurev.biochem.72.121801.161629</pub-id>
<pub-id pub-id-type="pmid">12676795</pub-id>
</element-citation>
</ref>
<ref id="B53-ijms-21-01286">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iqbal</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>C.X.</given-names>
</name>
<name>
<surname>Grundke-Iqbal</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>Tau in Alzheimer disease and related tauopathies</article-title>
<source/>Curr. Alzheimer Res.
          <year>2010</year>
<volume>7</volume>
<fpage>656</fpage>
<lpage>664</lpage>
<pub-id pub-id-type="doi">10.2174/156720510793611592</pub-id>
<pub-id pub-id-type="pmid">20678074</pub-id>
</element-citation>
</ref>
<ref id="B54-ijms-21-01286">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kins</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kurosinski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Nitsch</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Gotz</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice</article-title>
<source/>Am. J. Pathol.
          <year>2003</year>
<volume>163</volume>
<fpage>833</fpage>
<lpage>843</lpage>
<pub-id pub-id-type="doi">10.1016/S0002-9440(10)63444-X</pub-id>
<pub-id pub-id-type="pmid">12937125</pub-id>
</element-citation>
</ref>
<ref id="B55-ijms-21-01286">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueller</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>T.R.</given-names>
</name>
<name>
<surname>Kumagai</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dunphy</surname>
<given-names>W.G.</given-names>
</name>
</person-group>
<article-title>Myt1: A Membrane-Associated Inhibitory Kinase That Phosphorylates Cdc2 on Both Threonine-14 and Tyrosine-15</article-title>
<source/>Science
          <year>1995</year>
<volume>270</volume>
<fpage>86</fpage>
<pub-id pub-id-type="doi">10.1126/science.270.5233.86</pub-id>
<pub-id pub-id-type="pmid">7569953</pub-id>
</element-citation>
</ref>
<ref id="B56-ijms-21-01286">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Piwnica-Worms</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase</article-title>
<source/>Science
          <year>1992</year>
<volume>257</volume>
<fpage>1955</fpage>
<pub-id pub-id-type="doi">10.1126/science.1384126</pub-id>
<pub-id pub-id-type="pmid">1384126</pub-id>
</element-citation>
</ref>
<ref id="B57-ijms-21-01286">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Clarke</surname>
<given-names>P.R.</given-names>
</name>
<name>
<surname>Marcote</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Karsenti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Draetta</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Phosphorylation and activation of human cdc25-C by cdc2--cyclin B and its involvement in the self-amplification of MPF at mitosis</article-title>
<source/>EMBO J.
          <year>1993</year>
<volume>12</volume>
<fpage>53</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1002/j.1460-2075.1993.tb05631.x</pub-id>
<pub-id pub-id-type="pmid">8428594</pub-id>
</element-citation>
</ref>
<ref id="B58-ijms-21-01286">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chesnel</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bazile</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Pascal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kubiak</surname>
<given-names>J.Z.</given-names>
</name>
</person-group>
<article-title>Cyclin B dissociation from CDK1 precedes its degradation upon MPF inactivation in mitotic extracts of Xenopus laevis embryos</article-title>
<source/>Cell Cycle
          <year>2006</year>
<volume>5</volume>
<fpage>1687</fpage>
<lpage>1698</lpage>
<pub-id pub-id-type="doi">10.4161/cc.5.15.3123</pub-id>
<pub-id pub-id-type="pmid">16921258</pub-id>
</element-citation>
</ref>
<ref id="B59-ijms-21-01286">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sherwood</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Kung</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Roitelman</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Simoni</surname>
<given-names>R.D.</given-names>
</name>
<name>
<surname>Schimke</surname>
<given-names>R.T.</given-names>
</name>
</person-group>
<article-title>In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal</article-title>
<source/>Proc. Natl. Acad. Sci. USA
          <year>1993</year>
<volume>90</volume>
<fpage>3353</fpage>
<lpage>3357</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.90.8.3353</pub-id>
<pub-id pub-id-type="pmid">8386372</pub-id>
</element-citation>
</ref>
<ref id="B60-ijms-21-01286">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murray</surname>
<given-names>A.W.</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>M.J.</given-names>
</name>
<name>
<surname>Kirschner</surname>
<given-names>M.W.</given-names>
</name>
</person-group>
<article-title>The role of cyclin synthesis and degradation in the control of maturation promoting factor activity</article-title>
<source/>Nature
          <year>1989</year>
<volume>339</volume>
<fpage>280</fpage>
<lpage>286</lpage>
<pub-id pub-id-type="doi">10.1038/339280a0</pub-id>
<pub-id pub-id-type="pmid">2566918</pub-id>
</element-citation>
</ref>
<ref id="B61-ijms-21-01286">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Felix</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Karsenti</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Cdc2 H1 kinase is negatively regulated by a type 2A phosphatase in the Xenopus early embryonic cell cycle: Evidence from the effects of okadaic acid</article-title>
<source/>EMBO J.
          <year>1990</year>
<volume>9</volume>
<fpage>675</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="doi">10.1002/j.1460-2075.1990.tb08159.x</pub-id>
<pub-id pub-id-type="pmid">2155777</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<table-wrap id="ijms-21-01286-t001" orientation="portrait" position="float">
<object-id pub-id-type="pii">ijms-21-01286-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>Clinical features of individuals with different de novo mutations in the Protein Phosphatase 2 Regulatory Subunit B′ Delta (<italic>PPP2R5D</italic>) gene.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">PPP2R5D Mutations</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Glu197Lys</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Glu198Lys</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Glu200Lys</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Glu420Lys</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pro201Arg</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Pro53Ser</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Trp207Arg</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">Number of individuals diagnosed in the four studies designated as A, B, C, and D</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">B. 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">A. 6</td>
<td align="center" colspan="1" rowspan="2" valign="middle">A. 2</td>
<td align="center" colspan="1" rowspan="4" style="border-bottom:solid thin" valign="middle">B. 3</td>
<td align="center" colspan="1" rowspan="2" valign="middle">A. 1</td>
<td align="center" colspan="1" rowspan="2" valign="middle">A. 1</td>
<td align="center" colspan="1" rowspan="2" valign="middle">A. 1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">B. 2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">C. 2</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">B. 1</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">D. 1</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">B. 1</td>
<td align="center" colspan="1" rowspan="2" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">D. 3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Autism spectrum</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported (6/6)<break></break>B. Present (2/2)<break></break>C. Present (2/2)<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported<break></break>B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present (2/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present<break></break>B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]<break></break>C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]<break></break>D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Developmental<break></break>delay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Severe (6/6)<break></break>B. Severe (2/2)<break></break>C. Moderate (2/2)<break></break>D. Present (3/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Mild (2/2)<break></break>B. Present (2/2)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present (3/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported<break></break>D. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported<break></break>B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]<break></break>C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]<break></break>D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Unsupported walking</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. 26 months</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 6–8 years<break></break>B. 3–8 years<break></break>C. Not noted<break></break>D. Not noted</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 18–30 months<break></break>B. 28 months</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. 3–5 years (2/3), not walking (1/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 18 months<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 5 months to 3 years </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 1.2 years</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]<break></break>C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]<break></break>D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Speech</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. ~75 words and can form short sentences</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Nonverbal (5/6)<break></break>B. Nonverbal (1/2), and verbal (1/2)<break></break>C. Not noted<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Few words<break></break>B. Few words at 3 years</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Nonverbal (1/3), a few words (2/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. A few words<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Few words at 2.5 years (1/1)<break></break>B. Nonverbal (1/1)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Yes, poor intelligibility</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]<break></break>C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]<break></break>D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Intellectual disability (ID)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Moderate</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Severe (6/6)<break></break>B. Severe (3/3)<break></break>C. Moderate (2/2)<break></break>D. Present (1/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present<break></break>B. Severe</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present (2/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Moderate<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Severe</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Moderate</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]<break></break>C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]<break></break>D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Macrocephaly</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present (6/6)<break></break>B. Present (2/2)<break></break>C. Present (2/2)<break></break>D. Present (1/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Absent</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not present<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Absent</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]<break></break>C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]<break></break>D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Hypotonia</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present (6/6)<break></break>B. Present (2/2)<break></break>C. Present (2/2)<break></break>D. present (1/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present<break></break>B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported<break></break>B. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]<break></break>C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]<break></break>D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Number of individuals diagnosed in the four studies designated as A, B, C and D</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 6<break></break>B. 2<break></break>C. 2<break></break>D. 3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 2<break></break>B. 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. 3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 1<break></break>D. 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 1<break></break>B. 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. 1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>B. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]<break></break>C. [<xref ref-type="bibr" rid="B4-ijms-21-01286">4</xref>]<break></break>D. [<xref ref-type="bibr" rid="B27-ijms-21-01286">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Behavioral Abnormalities</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Anxiety in new situations</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported<break></break>B. Not tested<break></break>C. Not tested</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not tested<break></break>B. Not tested</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Aggressive, stereotypies, impulse control issues (2/3)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">-</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported<break></break>B. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]<break></break>B. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>C. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Seizures</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present (2/6)<break></break>B. Present (1/2)<break></break>C. Present (2/2)</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">-<break></break>B. Present </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">B. Absent</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Present (multifocal)<break></break>D. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Not reported<break></break>B. Not reported</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. Absent</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">A. [<xref ref-type="bibr" rid="B6-ijms-21-01286">6</xref>]<break></break>B. [<xref ref-type="bibr" rid="B1-ijms-21-01286">1</xref>]<break></break>C. [<xref ref-type="bibr" rid="B3-ijms-21-01286">3</xref>]</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>